TY - JOUR
T1 - Spontaneous (pathological) splenic rupture in a blastic variant of mantle cell lymphoma
T2 - A case report and literature review
AU - Lunning, Matthew A.
AU - Stetler-Stevenson, Maryalice
AU - Silberstein, Peter T.
AU - Zenger, Vincent
AU - Marti, Gerald E.
N1 - Funding Information:
1Mercy Cancer Center, Mason City, IA 2Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 3Flow and Image Cytometry Section, Laboratory of Stem Cell Biology, Division of Cell and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, National Institutes of Health, Bethesda, MD Submitted: Dec. 14, 2000; Revised: Mar. 17, 2001, Revised: Jun. 27, 2002; Accepted: July 1, 2002
PY - 2002/9
Y1 - 2002/9
N2 - Spontaneous (pathological) splenic rupture (SPSR) in hematological malignancies is rare. This report describes a 71-year-old male diagnosed with mantle cell lymphoma-blastic variant (MCL-BV) who experienced an SPSR a few days before the initial diagnosis. The patient underwent a splenectomy and recovered without incident. Partial remission was seen following several cycles of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone). However, relapse was rapid, with leukemic meningitis occurring several months later. It was successfully treated by intrathecal methotrexate and cranial spinal radiation. A progressive lymphocytosis developed, which responded to rituximab. Lymphadenopathy and skin involvement ensued, followed by pneumonia and death. The literature on SPSR in patients with MCL-BV and other lymphoproliferative disorders showed similar clinical and postoperative findings. Clinical presentation included Kehr's sign and acute abdominal pain. Postoperative findings included blood in the peritoneal cavity, multiple splenic hematomas, splenic infarcts, and splenic necrosis. Most strikingly, the majority of the patients reviewed appeared to have undergone some type of blastic transformation. One or any combination of these findings that has been noted above in addition to a bleeding diathesis could be the foundation to SPSR. We recommend consideration of splenic rupture in patients with a lymphoproliferative disorder coupled with rapid progression of marked or massive splenomegaly.
AB - Spontaneous (pathological) splenic rupture (SPSR) in hematological malignancies is rare. This report describes a 71-year-old male diagnosed with mantle cell lymphoma-blastic variant (MCL-BV) who experienced an SPSR a few days before the initial diagnosis. The patient underwent a splenectomy and recovered without incident. Partial remission was seen following several cycles of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone). However, relapse was rapid, with leukemic meningitis occurring several months later. It was successfully treated by intrathecal methotrexate and cranial spinal radiation. A progressive lymphocytosis developed, which responded to rituximab. Lymphadenopathy and skin involvement ensued, followed by pneumonia and death. The literature on SPSR in patients with MCL-BV and other lymphoproliferative disorders showed similar clinical and postoperative findings. Clinical presentation included Kehr's sign and acute abdominal pain. Postoperative findings included blood in the peritoneal cavity, multiple splenic hematomas, splenic infarcts, and splenic necrosis. Most strikingly, the majority of the patients reviewed appeared to have undergone some type of blastic transformation. One or any combination of these findings that has been noted above in addition to a bleeding diathesis could be the foundation to SPSR. We recommend consideration of splenic rupture in patients with a lymphoproliferative disorder coupled with rapid progression of marked or massive splenomegaly.
KW - Blastic transformation
KW - Chronic lymphocytic leukemia
KW - Cyclin D1
KW - Splenic infarct
KW - Splenomegaly
UR - http://www.scopus.com/inward/record.url?scp=0036753624&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036753624&partnerID=8YFLogxK
U2 - 10.3816/CLM.2002.n.018
DO - 10.3816/CLM.2002.n.018
M3 - Article
C2 - 12435285
AN - SCOPUS:0036753624
SN - 1526-9655
VL - 3
SP - 117
EP - 120
JO - Clinical Lymphoma
JF - Clinical Lymphoma
IS - 2
ER -